Home › Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet
 

Keywords :   


Merck Statement on FDA Advisory Committee for GRASTEK (Timothy Grass Pollen Allergen Extract), Mercks Investigational Sublingual Allergy Immunotherapy Tablet

2013-12-13 01:17:00| Merck.com - Product News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration (FDA) meeting to discuss GRASTEK (Timothy grass pollen allergen extract). Language: English Contact: MerckMedia:Pamela Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement committee advisory grass

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
10.05Senators request more aggressive approach on HPAI countermeasures
10.05Lidl raises pay to match Aldi in battle for staff
10.05Faisal Islam: Economy is getting better but people may not notice
10.05Sulfate-Free Foamable Solid Cleanser Patented by Johnson & Johnson
10.05Farm Progress America, May 10, 2024
10.05Farm Progress America, May 10, 2024
10.05Bank 'optimistic' as it edges closer to summer cut
10.05Comcast releases research on how viewers discover new TV content
More »